Literature DB >> 25934923

Cytokines in Graft-versus-Host Disease.

Andrea S Henden1, Geoffrey R Hill2.   

Abstract

Graft-versus-host disease (GVHD) is a complication of allogeneic bone marrow transplantation whereby transplanted naive and marrow-derived T cells damage recipient tissue through similar mechanisms to those that allow destruction of malignant cells, the therapeutic intent of bone marrow transplantation. The manifestations and severity of GVHD are highly variable and are influenced by the proportions of naive cells maturing along regulatory T cell, Th1, Th2, or Th17 phenotypes. This maturation is largely influenced by local cytokines, which, in turn, activate transcription factors and drive development toward a dominant phenotype. In addition, proinflammatory cytokines exert direct effects on GVHD target tissues. Our knowledge of the role that cytokines play in orchestrating GVHD is expanding rapidly and parallels other infective and inflammatory conditions in which a predominant T cell signature is causative of pathology. Because a broad spectrum of cytokine therapies is now routinely used in clinical practice, they are increasingly relevant to transplant medicine.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934923     DOI: 10.4049/jimmunol.1500117

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

1.  A proposed biology- and biomarker-based algorithm for management of acute GvHD.

Authors:  A M Ali; J F DiPersio; M A Schroeder
Journal:  Bone Marrow Transplant       Date:  2016-11-21       Impact factor: 5.483

2.  Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Authors:  Shane A Curran; Justin A Shyer; Erin T St Angelo; Lillian R Talbot; Sneh Sharma; David J Chung; Glenn Heller; Katharine C Hsu; Brian C Betts; James W Young
Journal:  Cancer Immunol Res       Date:  2016-12-06       Impact factor: 11.151

3.  GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Authors:  Mark D Bunting; Antiopi Varelias; Fernando Souza-Fonseca-Guimaraes; Iona S Schuster; Katie E Lineburg; Rachel D Kuns; Peter Fleming; Kelly R Locke; Nicholas D Huntington; Bruce R Blazar; Steven W Lane; Siok-Keen Tey; Kelli P A MacDonald; Mark J Smyth; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Blood       Date:  2016-12-07       Impact factor: 22.113

4.  ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.

Authors:  Brad Griesenauer; Hua Jiang; Jinfeng Yang; Jilu Zhang; Abdulraouf M Ramadan; Jane Egbosiuba; Khaled Campa; Sophie Paczesny
Journal:  J Immunol       Date:  2019-04-12       Impact factor: 5.422

Review 5.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

6.  Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation.

Authors:  I Petruskevicius; M Ludvigsen; R Hjortebjerg; B S Sørensen; P Kamper; M Vase; L G Oestgaard; B Nielsen; B Honoré; M Bjerre; G A Rabinovich; F A d'Amore
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

7.  Stem cell transplantation impairs dendritic cell trafficking and herpesvirus immunity.

Authors:  Carol A Wilke; Mathew M Chadwick; Paul R Chan; Bethany B Moore; Xiaofeng Zhou
Journal:  JCI Insight       Date:  2019-09-19

8.  Early T Cell Activation Metrics Predict Graft-versus-Host Disease in a Humanized Mouse Model of Hematopoietic Stem Cell Transplantation.

Authors:  Nicholas J Hess; Amy W Hudson; Peiman Hematti; Jenny E Gumperz
Journal:  J Immunol       Date:  2020-05-22       Impact factor: 5.422

9.  B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Authors:  R M Saliba; S Sarantopoulos; C L Kitko; A Pawarode; S C Goldstein; J Magenau; A M Alousi; T Churay; H Justman; S Paczesny; P Reddy; D R Couriel
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

10.  Newly found arsons ignite the fire of gut GVHD.

Authors:  Defu Zeng
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.